RegeneRx Biopharmaceuticals, Inc.
RGRX
$0.0002
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 76.80K | 76.80K | 76.80K | 76.80K | 76.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.80K | 76.80K | 76.80K | 76.80K | 76.80K |
| Cost of Revenue | -- | -- | 0.00 | 5.70K | 6.20K |
| Gross Profit | 76.80K | 76.80K | 76.80K | 71.10K | 70.60K |
| SG&A Expenses | 1.44M | 1.48M | 1.54M | 1.65M | 1.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.44M | 1.48M | 1.54M | 1.66M | 1.45M |
| Operating Income | -1.36M | -1.40M | -1.46M | -1.58M | -1.37M |
| Income Before Tax | -1.69M | -1.73M | -1.79M | -1.85M | -1.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.69 | -1.73 | -1.79 | -1.85 | -1.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.69M | -1.73M | -1.79M | -1.85M | -1.64M |
| EBIT | -1.36M | -1.40M | -1.46M | -1.58M | -1.37M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.18 | -1.20 | -1.24 | -1.29 | -1.16 |
| Normalized Basic EPS | -0.74 | -0.75 | -0.78 | -0.83 | -0.75 |
| EPS Diluted | -1.16 | -1.19 | -1.24 | -1.29 | -1.16 |
| Normalized Diluted EPS | -0.74 | -0.75 | -0.78 | -0.83 | -0.75 |
| Average Basic Shares Outstanding | 5.74M | 5.74M | 5.74M | 5.74M | 5.64M |
| Average Diluted Shares Outstanding | 5.74M | 5.74M | 5.74M | 5.74M | 5.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |